Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2013

View Archived Issues

Ascorbix presents novel agents for cancer

Italian researchers patent new photosensitizing agents

Suzhou NeuPharma discloses novel arctigenin derivatives for cancer

HSCI obtains approval in Ukraine for Neovasculgen

Biosantech initiates phase I/II trial of synthetic AIDS vaccine Tat Oyi

Activin betaC expression plays a role in the progression of prostate disease

HAT-01: a novel herbal preparation for the treatment of atopic dermatitis

Katanin enzyme complexes necessary for male fertility

UCB reflects on achievements of 2012

Researchers at Ascendis Pharma synthesize novel prodrugs of paliperidone

Promethera Biosciences opens French site in phase I/II HepaStem trial

BioLineRx's candidate for severe and persistent asthma to enter main pipeline

Novan Therapeutics reports preclinical data for topical sebum inhibitor

Trophos confirms positive interim review for pivotal olesoxime trial

Life Technologies signs stem cell research agreement

NIBP expression shows partial correlation with breast tumor staging

FDA accepts filing of BLA for recombinant factor IX Fc fusion protein

FDA agrees with La Jolla Pharmaceutical's proposed IND for LJPC-501

Immuron reports preclinical data for IMM-529

Sarepta Therapeutics reports data from non-human primate study of AVI-7288

VX-787 shows antiviral activity in phase II influenza challenge study

EMA grants orphan drug status to Prothena's candidate for amyloid light-chain amyloidosis

Researchers at Merck KGaA design new RON inhibitors

HH1.5 shows potential as a novel biomarker in prostate cancer

Verona's RPL-554 demonstrates anti-inflammatory activity in exploratory trial

Health Canada declines to approve Theratechnologies' NDS for Egrifta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...